Alvotech Names Lisa Graver as General Counsel, relocating to Reykjavik as the biosimilar company shifts from build-phase to litigation...

Shao-Lee Lin named CEO of Cue Biopharma to lead clinical-stage transformation with Phase 2 anti-IgE allergy program and early...

Pacira's pipeline approaches critical data readouts including ZILRETTA shoulder OA Phase 3 results expected before year-end, with multiple binary...

Revumenib post-transplant rate rises to 48% as Syndax exceeds $100M quarterly sales, reshaping the commercial trajectory of its KMT2A-rearranged...

Setmelanotide gains European Commission approval for acquired hypothalamic obesity, delivering 19.8% placebo-adjusted BMI reduction across 120 patients.

Cue Biopharma names new CEO and advances allergic disease program with Phase 2 data expected in second half 2026.

Alvotech General Counsel Tanya Zharov departs after six years; Lisa Graver named successor amid pipeline expansion and market commoditization.

Syndax reports Revuforj transplant rate rises to 50% in KMT2A patients, reshaping the commercial outlook for stem cell transplant...

Setmelanotide gains EU approval for hypothalamic obesity, marking the first approved treatment for a rare condition affecting 10,000 patients...

Pacira Reports 5% Revenue Growth in Q1 2026 on EXPAREL Volume Gains, with 7% increase in hospital and surgical...